XenoPort Announces Presentation Of Preclinical Data For Acamprosate Prodrug At Fragile X Syndrome Conference
XenoPort, Inc. (Nasdaq:XNPT) announced that it has discovered a novel prodrug that has the potential to improve significantly the blood concentration of acamprosate compared with the currently approved formulation of acamprosate.